Zhendong Pharmacy(SZ:300158)2022-12-07 08:44Group 1: Major Asset Restructuring - The purpose of the major asset restructuring is to enhance the company's core competitiveness by acquiring products with strong market presence, such as Calcium D3 tablets and granules, which have high market recognition and share [3] - The acquisition will allow the company to quickly gain access to competitive products, diversify its product range, and reduce operational risks [3] - The integration of Calcium D3 products with existing offerings aims to boost sales of other OTC products, leveraging the growing health product market [3] Group 2: Impact on Business Strategy - Post-restructuring, the company will have a richer product line and gain access to competitive pharmaceutical varieties, facilitating rapid growth [3] - The acquired company, Kangyuan Pharmaceutical, will become a wholly-owned subsidiary, benefiting from improved governance and management through capital market support [4] - The transaction aligns with both parties' strategic goals, maximizing profits and achieving strategic synergy [4] Group 3: Dividend and Profit Distribution - The board will consider investors' reasonable demands for returns, discussing profit distribution plans, including stock dividend proposals, based on business development and financial needs [4] - Any progress on profit distribution will be announced in accordance with regulations [4] Group 4: Sales and Market Performance - The sales volume of the company's main product, Yanshu Injection, is expected to remain stable this year, with ongoing clinical trials for new formulations [5] - The company aims to strengthen its sales team as a key strategy for future growth, addressing past mismatches in brand, capacity, and marketing [6] - The company has implemented significant reforms in its marketing structure, relocating its marketing team to Beijing to enhance talent acquisition and information flow [6] Group 5: Future Development Plans - The company plans to continue investing in traditional Chinese medicine and improve its supply chain to support farmers, with significant benefits already observed [5] - The focus remains on developing traditional Chinese medicine oncology drugs, with a clear strategy for future research and development [6]